Helene Rundqivst, Piergiorgio Percipalle, Jonas Bergh, Chad M. Kurylo, John S. Condeelis, Kristian Haller, C. David Allis, Ayuko Hoshino, David Lyden, Julian Petersen, Varsha Prakash, M. Angela Nieto, Scott C. Blanchard, Randall A. Dass, Ayako Hashimoto, Jake E. Batchelder, Johan Hartman, Brittany Carson, Petra Sekyrova, Ann-Kristin Östlund Farrants, Kristian Pietras, C. Theresa Vincent, Igor Adameyko, Matthew Parks, Jennifer M. Feenstra, Michael Andäng, Yuan Guo, Denis Drygin, Swedish Cancer Society, Swedish Research Council, Magnus Bergvall Foundation, America Scandinavia Foundation, Ake Wiberg Foundation, Karolinska Institutet Foundation, Uppsala University, National Institutes of Health (US), Czech Grant Agency, Lund University, European Research Council, Knut and Alice Wallenberg Foundation, European Commission, Nieto, M. Ángela, and Nieto, M. Ángela [0000-0002-3538-840X]
Ribosome biogenesis is a canonical hallmark of cell growth and proliferation. Here we show that execution of Epithelial-to-Mesenchymal Transition (EMT), a migratory cellular program associated with development and tumor metastasis, is fueled by upregulation of ribosome biogenesis during G1/S arrest. This unexpected EMT feature is independent of species and initiating signal, and is accompanied by release of the repressive nucleolar chromatin remodeling complex (NoRC) from rDNA, together with recruitment of the EMT-driving transcription factor Snai1 (Snail1), RNA Polymerase I (Pol I) and the Upstream Binding Factor (UBF). EMT-associated ribosome biogenesis is also coincident with increased nucleolar recruitment of Rictor, an essential component of the EMT-promoting mammalian target of rapamycin complex 2 (mTORC2). Inhibition of rRNA synthesis in vivo differentiates primary tumors to a benign, Estrogen Receptor-alpha (ERα) positive, Rictor-negative phenotype and reduces metastasis. These findings implicate the EMT-associated ribosome biogenesis program with cellular plasticity, de-differentiation, cancer progression and metastatic disease., This work was supported by the Swedish Cancer Society (Cancerfonden), Swedish Research Council (Vetenskapsrådet, Young Investigator Grant and Project grant), VINNMER–Marie Curie international qualification, Georg and Eva Klein Visiting Junior Scientist Award, Sigurd och Elsa Goljes minne, Magnus Bergvall foundation, Alex and Eva Wallström foundation, American Scandinavia Foundation (Sverige Amerika Stiftelsen), Åke Wiberg foundation, Tore Nilsson foundation, the Karolinska Institute funds and IGP, Uppsala University (to C.T.V.). S.C.B, C.T.V, R.A.D. and M.M.P were supported by the Tri-Institutional Stem Cell Initiative funded by the Starr Foundation and the National Institutes of Health (GM079238). P.S. was supported by Cancerfonden post-doctoral fellowship and the Grant Agency of the Czech Republic (GA15-20818S). J.P was supported by the Swedish Research Council (Vetenskapsrådet). “K.P. is the Göran &; Birgitta Grosskopf Professor at Lund University and supported by the ERC Consolidator grant TUMORGAN”. The confocal imaging facility and FACS facility at KI were supported by Knut &; Alice Wallenberg foundation.